Search This Blog

Monday, September 26, 2016

FDA Approves Amgen's AMJEVITA™ (Adalimumab-Atto) For Treatment Of Seven Inflammatory Diseases

First Regulatory Approval for Company's Biosimilar Portfolio
First Biosimilar Adalimumab Approved by FDA

Amgen - Investors - RSS Content

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.